• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].

作者信息

Beuzeboc P, Pierga J Y, Lyonnet D S, Couturier J, Pouillart P

机构信息

Service d'oncologie médicale, Institut Curie, Paris, France.

出版信息

Bull Cancer. 1996 Apr;83(4):324-7.

PMID:8680084
Abstract

Dihydropyrimidine dehydrogenase (DPD) is the principal enzyme involved in the catabolism of 5 fluorouracil (5 FU). The clinical importance of DPD has recently been demonstrated wit the identification of rare cases presenting a severe toxicity to 5 FU related to proven DPD deficiency. We report a new case in a patient with concurrent congenital osteogenesis imperfecta. We were surprised to find another similar association reported by Lyss. It is tempting to speculate that DPD activity may be abnormally regulated in osteogenesis imperfecta patients.

摘要

相似文献

1
[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].
Bull Cancer. 1996 Apr;83(4):324-7.
2
Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta.
Eur J Cancer. 1996 Feb;32A(2):369-70. doi: 10.1016/0959-8049(95)00573-0.
3
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.与对照组相比,严重5-氟尿嘧啶(5-FU)相关毒性患者中,二氢嘧啶脱氢酶(DPD)基因第14内含子5'剪接供体位点常见点突变的患病率。
Clin Cancer Res. 2001 Sep;7(9):2832-9.
4
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.二氢嘧啶脱氢酶缺乏症与氟尿嘧啶相关毒性
Br J Cancer. 1999 Feb;79(3-4):627-30. doi: 10.1038/sj.bjc.6690098.
5
Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity.一名日本5-氟尿嘧啶中毒患者二氢嘧啶脱氢酶基因新突变的鉴定。
Clin Cancer Res. 1998 Dec;4(12):2999-3004.
6
[Dihydropyrimidine dehydrogenase activity and its genetic aberrations].[二氢嘧啶脱氢酶活性及其基因异常]
Gan To Kagaku Ryoho. 2006 Aug;33(8):1041-8.
7
[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].[氟尿嘧啶类辅助治疗在结直肠癌中疗效及毒性预测的药物遗传学研究]
Magy Onkol. 2007;51(2):113-25. Epub 2007 Jul 29.
8
Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.二氢嘧啶脱氢酶缺乏症:一种导致对基于5-氟尿嘧啶的化疗产生严重不良反应的药物遗传学缺陷。
Oncol Nurs Forum. 1997 Jan-Feb;24(1):83-8.
9
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.二氢嘧啶脱氢酶与5-氟尿嘧啶的疗效和毒性
Eur J Cancer. 2004 May;40(7):939-50. doi: 10.1016/j.ejca.2003.12.004.
10
Dehydropyrimidine dehydrogenase deficiency in a cancer patient undergoing 5-fluorouracil chemotherapy.一名接受5-氟尿嘧啶化疗的癌症患者出现二氢嘧啶脱氢酶缺乏症。
Anticancer Res. 2004 Mar-Apr;24(2C):1091-2.

引用本文的文献

1
Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.生物体液中二氢尿嘧啶/尿嘧啶比率的昼夜节律:二氢嘧啶脱氢酶水平的潜在生物标志物。
Br J Pharmacol. 2004 Feb;141(4):616-23. doi: 10.1038/sj.bjp.0705651. Epub 2004 Jan 26.